Zusammenfassung
Ergebnisse retrospektiver Studien zum differenzierten Schilddrüsenkarzinom zeigen, dass Patienten mit echter Infiltration angrenzender Organe (Stadium T4 der TNM-Klassifikation 2002) bezüglich der lokoregionären Kontrolle von einer externen Strahlentherapie profitieren, bei R2-Situation sogar bezüglich des krankheitsspezifischen Überlebens. Die deutsche MSDS-Studie konnte aufgrund einer geringen Anzahl randomisierter Patienten den Stellenwert der externen Strahlentherapie beim differenzierten Karzinom mit Kapselüberschreitung nur teilweise klären. Internationale Leitlinien sehen übereinstimmend eine kleine Gruppe von Hochrisikopatienten, die nach optimaler Operation und Radioiodtherapie von einer externen Strahlentherapie profitieren. Beim undifferenzierten Schilddrüsenkarzinom ist die externe Strahlentherapie, auch bei Fernmetastasierung, in der Regel indiziert. Sie sollte mit mindestens 40 Gy durchgeführt werden und ermöglicht eine lokoregionäre Kontrolle in 60–80% der Fälle. Für Patienten ohne Fernmetastasen und mit mindestens einer makroskopischen Komplettresektion kann eine trimodale Therapie von Nutzen sein.
Abstract
Results of retrospective studies on differentiated thyroid cancer suggest that patients with true invasion of adjacent organs (stage T4 in TNM 2002) benefit from external beam radiotherapy regarding locoregional control and in an R2 situation even regarding disease-specific survival. The German MSDS trial could only partly clarify the role of external beam radiotherapy in differentiated thyroid cancer with extracapsular extension. International guidelines currently recognize a small high-risk group which benefits from external beam radiotherapy after optimal surgery and radioiodine treatment. In undifferentiated thyroid cancer external-beam radiotherapy is usually indicated even in the presence of distant metastases. It should be administered with at least 40 Gy and achieves locoregional control in 60-80% of cases. Patients without distant metastases and at least macroscopically complete resection might benefit from trimodal treatment.
Literatur
Besic N, Auersperg M, Us-Krasovec M et al (2001) Effect of primary treatment on survival in anaplastic thyroid carcinoma. Eur J Surg Oncol 27:260–264
Biermann M, Pixberg MK, Schuck A et al (2003) Multicenter Study Differentiated Thyroid Carcinoma (MSDS). Diminished acceptance of adjuvant external beam radiotherapy. Nuklearmedizin 42:244–250
Biermann M, Pixberg MK, Riemann B et al (2009) Clinical outcomes of adjuvant external-beam radiotherapy for differentiated thyroid cancer. Results after 874 patient-years of follow-up in the MSDS trial. Nuklearmedizin 48:89–98
Brierley JD, Tsang RW (1999). External-beam radiation therapy in the treatment of differentiated thyroid cancer. Semin Surg Oncol 16:42–49
Brierley J, Tsang R, Simpson WJ et al (1996) Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 6:305–310
British Thyroid Association, Royal College of Physicians (2007) Guidelines for the management of thyroid cancer In: Perros P (ed) Report of the Thyroid Cancer Guidelines Update Group, 2nd edn. Royal College of Physicians, London
Chow SM, Yau S, Kwan CK et al (2006) Local and regional control in patients with papillary thyroid carcinoma: specific indications of external radiotherapy and radioactive iodine according to T and N categories in AJCC, 6th edn. Endocr Relat Cancer 13:1159–1172
Cooper DS, Doherty GM, Haugen BR et al (2009) Revised American Thyroid Association Management Guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167–1214
De Crevoisier R, Baudin E, Bachelot A et al (2004) Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys 60:1137–1143
Dralle H (2008) Maligne Schilddrüsentumoren, In: Deutsche Krebsgesellschaft (Hrsg.) Kurzgefasste Interdisziplinäre Leitlinien 2008. Zuckschwerdt, München
Farahati J, Reiners C, Stuschke M et al (1996) Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4). Cancer 77:172–180
Fersht N, Vini L, A’Hern R, Harmer C (2001) The role of radiotherapy in the management of elevated calcitonin after surgery for medullary thyroid cancer. Thyroid 11:1161–1168
Ford D, Giridharan S, McConkey C et al (2003) External beam radiotherapy in the management of differentiated thyroid cancer. Clin Oncol (R Coll Radiol) 15:337–341
Haigh PI, Ituarte PH, Wu HS et al (2001) Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 91:2335–2242
Hyer SL, Vini L, A’Hern R, Harmer C (2000) Medullary thyroid cancer: multivariate analysis of prognostic factors influencing survival. Eur J Surg Oncol 26:686–690
Kebebew E, Greenspan FS, Clark OH et al (2005) Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 103:1330–1335
Keum KC, Suh YG, Koom WS et al (2006) The role of postoperative external-beam radiotherapy in the management of patients with papillary thyroid cancer invading the trachea. Int J Radiat Oncol Biol Phys 65:474–480
Lai HW, Lee CH, Chen JY et al (2006) Insular thyroid carcinoma: collective analysis of clinicohistologic prognostic factors and treatment effect with radioiodine or radiation therapy. J Am Coll Surg 203:715–722
Levendag PC, De Porre PM, Putten WL van (1993) Anaplastic carcinoma of the thyroid gland treated by radiation therapy. Int J Radiat Oncol Biol Phys 26:125–128
Lin JD, Chao TC, Hsueh C (2007) Clinical characteristics of poorly differentiated thyroid carcinomas compared with those of classical papillary thyroid carcinomas. Clin Endocrinol (Oxf) 66:224–228
McWilliams RR, Giannini C, Hay ID et al (2003) Management of brain metastases from thyroid carcinoma: a study of 16 pathologically confirmed cases over 25 years. Cancer 98:356–362
Mitchell G, Huddart R, Harmer C (1999) Phase II evaluation of high dose accelerated radiotherapy for anaplastic thyroid carcinoma. Radiother Oncol 50:33–38
Nutting CM, Convery DJ, Cosgrove VP et al (2001) Improvements in target coverage and reduced spinal cord irradiation using intensity-modulated radiotherapy (IMRT) in patients with carcinoma of the thyroid gland. Radiother Oncol 60:173–180
Pacini F, Schlumberger M, Dralle H et al (2006) European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787–803
Patel KN, Shaha AR (2006) Poorly differentiated and anaplastic thyroid cancer. Cancer Control 13:119–128
Schuck A, Biermann M, Pixberg MK et al (2003) Acute toxicity of adjuvant radiotherapy in locally advanced differentiated thyroid carcinoma. First results of the multicenter study differentiated thyroid carcinoma (MSDS). Strahlenther Onkol 179:832–839
Schwartz DL, Lobo MJ, Ang KK et al (2009) Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment. Int J Radiat Oncol Biol Phys 74:1083–1091
Tennvall J, Lundell G, Wahlberg P et al (2002) Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer 86:1848–1853
Wang Y, Tsang R, Asa S et al (2006) Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimens. Cancer 107:1786–1792
Interessenkonflikt
Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht..
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Vordermark, D., Pelz, T. & Sieker, F. Die Rolle der externen Strahlentherapie bei der Behandlung des Schilddrüsenkarzinoms. Onkologe 16, 695–700 (2010). https://doi.org/10.1007/s00761-010-1871-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00761-010-1871-1